Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Rapport Therapeutics, Inc.
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
May 08, 2025
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics to Participate in Upcoming Investor Conferences
April 22, 2025
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
March 21, 2025
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 11, 2025
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
March 03, 2025
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2025
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
January 09, 2025
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
January 09, 2025
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
December 06, 2024
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
November 14, 2024
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
November 07, 2024
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
November 04, 2024
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
September 05, 2024
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
August 29, 2024
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
August 08, 2024
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
July 29, 2024
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
June 12, 2024
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPP
Rapport Therapeutics Announces Pricing of Initial Public Offering
June 06, 2024
From
Rapport Therapeutics, Inc.
Via
GlobeNewswire
Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors
March 19, 2024
From
Rapport Therapeutics, Inc.
Via
Business Wire
Rapport Therapeutics Appoints Chief People Officer
February 28, 2024
From
Rapport Therapeutics, Inc.
Via
Business Wire
Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors
January 16, 2024
From
Rapport Therapeutics, Inc.
Via
Business Wire
Rapport Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Rapport Therapeutics, Inc.
Via
Business Wire
Rapport Therapeutics Appoints Chief Financial Officer
October 30, 2023
From
Rapport Therapeutics, Inc.
Via
Business Wire
Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member
September 07, 2023
From
Rapport Therapeutics, Inc.
Via
Business Wire
Rapport Therapeutics Raises $150 Million in Series B Funding Round and Announces Key Board Appointments to Further Advance Precision Neuromedicine Platform
August 23, 2023
From
Rapport Therapeutics, Inc.
Via
Business Wire
Rapport Therapeutics Names Scientific Advisory Board
June 29, 2023
From
Rapport Therapeutics, Inc.
Via
Business Wire
Rapport Therapeutics Launches with $100 Million to Transform the Treatment of Neurological Disease through the Discovery and Development of Precision Therapies
March 07, 2023
From
Rapport Therapeutics, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.